Wanbond announced that the wholly-owned subsidiary Wanbond Pharmaceutical Group obtained US FDA orphan drug qualification for the treatment of neonatal hypoxic ischemic encephalopathy (HIE). Huperzine A mainly inhibits acetylcholinesterase, has anti-inflammatory, anti-oxidative stress, and neuroprotective effects, and has been marketed.
万邦德：子公司石杉碱甲获FDA孤儿药认定
Wan Bond: Subsidiary Huperzine A was certified as an orphan drug by the FDA
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.